FDA approves Merck's KEYTRUDA and WELIREG combination for kidney cancer
Tweet Send to a Friend
The U.S. Food and Drug Administration approved Merck's (NYSE: MRK) KEYTRUDA and KEYTRUDA QLEX, each in combination with WELIREG, for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


